Phase II study of oral S-1 plus cisplatin with bevacizumab for advanced non-squamous non-small cell lung cancer

Kaira, Kyoichi; Tomizawa, Yoshio; Yoshino, Reiko; Miura, Yoshiko; Yoshii, Akihiro; Iwasaki, Yasuki; Koga, Yasuhiko; Ono, Akiko; Hisada, Takeshi; Minato, Koichi; Sato, Koji; Kazama, Toshifumi; Ishihara, Shinichi; Kohyama, Kenya; Fueki, Naoto; Saito, Ryusei; Sunaga, Noriaki

doi:10.1016/j.lungcan.2013.07.008

Cited by 6 publications

(6 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To expand the clinical utility of bevacizumab in front-line treatment of patients with non-squamous NSCLC, a variety of combinations have been reported with promising results. These combinations include regimens with oxaliplatin [31][32][33] as a platinum agent, vinorelbine [34], docetaxel [33,[35][36][37], pemetrexed [32,[38][39][40][41], nanoparticle albumin-bound paclitaxel [42], oral S-1 [43,44], and ixabepilone [40]. The present study provided further evidence of the high efficacy of a 3-drug combination chemotherapy including bevacizumab for the treatment of advanced nonsquamous NSCLC.…”

Section: Discussionsupporting

confidence: 55%

Phase II study of carboplatin, docetaxel and bevacizumab for chemotherapy-naïve patients with advanced non-squamous non-small cell lung cancer

Takiguchi

Iwasawa

Minato³

et al. 2014

Int J Clin Oncol

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 55%

Phase II study of carboplatin, docetaxel and bevacizumab for chemotherapy-naïve patients with advanced non-squamous non-small cell lung cancer

Takiguchi

Iwasawa

Minato³

et al. 2014

Int J Clin Oncol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Bevacizumab, an inhibitor of vascular endothelial growth factor, has been used in the treatment of metastatic malignancies, particularly colon, ovary and non-small cell carcinoma of the lung. A few reports of intestinal perforation were recorded [59][60][61] followed by a recent estimate of 3% perforation rate in a series of bevacizumab-treated patients with nonsquamous non-small cell lung cancer [62] . Another biological agent, interleukin-2 (IL-2) used in high dose resulted in remission in some patients with metastatic melanoma and renal cell carcinoma with about half of these experiencing complete remission.…”

Section: Medication-related Causesmentioning

confidence: 99%

Spontaneous free perforation of the small intestine in adults

Freeman¹

2014

WJG

View full text Add to dashboard Cite

show abstract

“…In most patients, the disease is already advanced at the time of the initial diagnosis, and hence, palliative radiation therapy and chemotherapy are initiated as first-line regimens. 2,3 The proliferation of new blood vessels, originating from the existing vascular system, is needed both for tumor growth and metastatic dissemination. [4][5][6] Monoclonal antibodies, such as bevacizumab, targeting vascular endothelial growth factor to inhibit tumoral angiogenesis, suppress tumor growth.…”

Section: Results: According To Biopsy 37 Patients Had Nsclc (22 Adenmentioning

confidence: 99%

“…Such targeted drugs are increasingly used in combination with standardized platinum-based chemotherapy. 2,7 Patient treatment hence becomes more individualized to tumor biology, taking into account angiogenic status, which still needs to be learned and understood. 7,8 The traditional monitoring of therapeutic effects, being based on morphological criteria on computed tomography (CT), may lead to a misinterpretation of antiangiogenic effects.…”

Section: Results: According To Biopsy 37 Patients Had Nsclc (22 Adenmentioning

confidence: 99%

Assessment of Bronchial and Pulmonary Blood Supply in Non-Small Cell Lung Cancer Subtypes Using Computed Tomography Perfusion

Nguyen-Kim¹,

Frauenfelder²,

Strobel³

et al. 2015

Investigative Radiology

View full text Add to dashboard Cite

OBJECTIVES: The aim of this study was to investigate the dual blood supply of non-small cell lung cancer (NSCLC) and its association with tumor subtype, size, and stage, using computed tomography perfusion (CTP). MATERIALS AND METHODS: A total of 54 patients (median age, 65 years; range, 42-79 years; 15 women, 39 men) with suspected lung cancer underwent a CTP scan of the lung tumor. Pulmonary and bronchial vasculature regions of interest were used to calculate independently CTP parameters (blood flow [BF], blood volume [BV], and mean transit time [MTT]) of the tumor tissue. The mean and maximum pulmonary and bronchial perfusion indexes (PImean and PImax) were calculated. The tumoral volume and the largest tumoral diameter were assessed. Differences in CTP parameters and indexes among NSCLC subtypes, tumor stages and tumor dimensions were analyzed using non-parametric tests. RESULTS: According to biopsy, 37 patients had NSCLC (22 adenocarcinomas [ACs], 8 squamous cell carcinomas [SCCs], 7 large-cell carcinomas [LCC]). The mean bronchial BF/pulmonary BF, bronchial BV/pulmonary BV, and bronchial MTT/pulmonary MTT was 41.2 ± 30.0/36.9 ± 24.2 mL/100 mL/min, 11.4 ± 9.7/10.4 ± 9.4 mL/100 mL, and 11.4 ± 4.3/14.9 ± 4.4 seconds, respectively. In general, higher bronchial BF than pulmonary BF was observed in NSCLC (P = 0.014). Using a tumoral volume cutoff of 3.5 cm, a significant difference in pulmonary PImax was found (P = 0.028). There was a significantly higher mean pulmonary BF in LCCs and SCCs compared with ACs (P = 0.018 and P = 0.044, respectively), whereas the mean bronchial BF was only significantly higher in LCCs compared with ACs (P = 0.024). Correspondingly, the PImax was significantly higher in LCCs and SCCs than in ACs (P = 0.001 for both). Differences between bronchial and pulmonary PImean and PImax among T stages and Union Internationale Contre le Cancer stages were not statistically significant (P values ranging from 0.691 to 0.753). CONCLUSIONS: The known dual blood supply of NSCLC, which depends on tumor size and histological subtype, is reflected in CTP parameters, with parameters depending both on tumor size and histological subtype. This has to be accounted for when analyzing NSCLC with CTP.This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially. http://creativecommons.org/licenses/by-nc-nd/3.0.

show abstract

Phase II study of oral S-1 plus cisplatin with bevacizumab for advanced non-squamous non-small cell lung cancer

Cited by 6 publications

References 26 publications

Phase II study of carboplatin, docetaxel and bevacizumab for chemotherapy-naïve patients with advanced non-squamous non-small cell lung cancer

Phase II study of carboplatin, docetaxel and bevacizumab for chemotherapy-naïve patients with advanced non-squamous non-small cell lung cancer

Spontaneous free perforation of the small intestine in adults

Assessment of Bronchial and Pulmonary Blood Supply in Non-Small Cell Lung Cancer Subtypes Using Computed Tomography Perfusion

Contact Info

Product

Resources

About